Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1978 2
1979 4
1980 2
1981 6
1982 6
1983 4
1984 4
1985 2
1986 2
1987 3
1989 2
1990 4
1991 2
1992 5
1993 1
1995 1
1998 4
1999 2
2000 1
2001 1
2004 2
2006 1
2009 1
2010 2
2011 2
2012 4
2013 2
2014 4
2015 3
2016 3
2017 5
2018 4
2019 2
2020 2
2021 2
2022 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Among authors: carinelli s. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
Diffuse uterine leiomyomatosis.
Fedele L, Zamberletti D, Carinelli S, Motta T, Candiani GB. Fedele L, et al. Among authors: carinelli s. Acta Eur Fertil. 1982 Sep;13(3):125-31. Acta Eur Fertil. 1982. PMID: 7183044 No abstract available.
Treatment options for pregnant women with ovarian tumors.
Mancari R, Tomasi-Cont N, Sarno MA, Azim HA Jr, Franchi D, Carinelli S, Biglia N, Colombo N, Peccatori FA. Mancari R, et al. Among authors: carinelli s. Int J Gynecol Cancer. 2014 Jul;24(6):967-72. doi: 10.1097/IGC.0000000000000161. Int J Gynecol Cancer. 2014. PMID: 24978707 Review.
Endometriosis and ovarian cancer.
Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L, Crosignani PG. Vercellini P, et al. Among authors: carinelli s. Am J Obstet Gynecol. 1993 Jul;169(1):181-2. doi: 10.1016/0002-9378(93)90159-g. Am J Obstet Gynecol. 1993. PMID: 8392791
101 results